Similar companies
Income Statement (USD)
| Q3 '24 | QoQ | |
|---|---|---|
| Revenue | 1.1M | 18.9% |
| Gross Profit | -520,000 | 48.8% |
| Cost of Revenue | 1.6M | 16.5% |
| Operating expense | 570,000 | 50.4% |
| Net Income | -1.1M | 22.3% |
| EBITDA | -980,000 | 23.8% |
Balance Sheet (USD)
| Q3 '24 | QoQ | |
|---|---|---|
| Total Assets | 13M | 5.6% |
| Total Liabilities | 6.9M | 1.2% |
| Total Equity | 6.5M | 11.9% |
| Shares Outstanding | 18M | 4.1% |
Cash Flow (USD)
| Q3 '24 | QoQ | |
|---|---|---|
| Cash from operations | -47,000 | 35.4% |
| Cash from investing | 9,200 | 0% |
| Cash from financing | 6,800 | 0.1% |
EPS
Financial Highlights for China Pharma Holding in Q3 '24
China Pharma Holding reported a revenue of 1.1M, which is a 18.9% change from the previous quarter. An increase in revenue typically indicates growing demand for the company's products or services. This positive change in revenue is a good sign, suggesting that the company's sales are moving in the right direction.
Gross Profit stood at -520,000, marking a 48.8% change since the last quarter. Gross profit showcases the efficiency in production and sales processes.
Cost of Revenue was 1.6M, a -16.5% difference from the previous quarter. A rising cost of revenue may suggest increased production or sales costs, which can impact margins. However, if accompanied by a proportionate rise in revenue, it could indicate scaling operations.
Operating Expenses for this period were 570,000, showing a 50.4% change from the last quarter. Operating expenses cover the costs of running daily business operations. A significant increase might indicate inefficiencies or investments in growth, while a decrease could suggest cost-saving measures or potential underinvestment in key areas.
Net Income for the quarter was -1.1M, showing a 22.3% change from the prior quarter. Net income provides a clear picture of the company's profitability after all expenses. An increase suggests the company is becoming more profitable, while a decrease may raise concerns about the company's financial health, unless there are specific one-time costs or investments.
The company's EBITDA for the quarter was -980,000, showing a 23.8% change from the previous period. EBITDA gives insight into the company's operational profitability, excluding non-operating expenses like interest and taxes. A rising EBITDA indicates strong operational performance, while a declining EBITDA may signal operational challenges or increased costs.
It was a positive quarter for China Pharma Holding with growth in revenue, gross profit, and net income. Higher operating expenses might indicate increased investments or potential inefficiencies.
